Key result
LASI-DAD panel improves PRS prediction ~35% and genotype imputation accuracy versus existing panels.
Why the study?
Genetic studies in India remain limited despite its large population and unique mixed genetic ancestry, requiring a foundational reference panel benchmark for future population studies and tailored medical interventions.
The LASI-DAD reference panel significantly improves genotype imputation accuracy and polygenic risk score predictive performance for Indian populations compared to existing panels.
India is the most populous country globally, yet genetic studies involving Indian individuals remain limited. The Indian population is composed of many founder groups and has a mixed genetic ancestry, including an ancestral component not observed anywhere outside of India. This presents a unique opportunity to uncover novel disease variants and develop tailored medical interventions. To facilitate genetic research in India, a crucial first step is to create a foundational resource that serves as a benchmark for future population studies and methods development. Thus, we constructed the largest and most nationally representative linkage disequilibrium (LD) and genotype imputation reference panels in India to date, using high-coverage whole-genome sequencing data of 2,680 participants from the Longitudinal Aging Study in India-Harmonized Diagnostic Assessment of Dementia (LASI-DAD). As an LD reference panel, LASI-DAD includes 69.5 million variants, representing 170% and 213% increases relative to the 1000 Genomes Project (1000G) and TOP-LD South Asian panels, respectively. Besides serving as an LD lookup panel, LASI-DAD facilitates various statistical analyses relying on precise LD estimates. In polygenic risk score (PRS) analyses, LASI-DAD improved the PRS predictive performance by 2.1% to 35.1% across traits and studies. As an imputation reference panel, LASI-DAD enhanced imputation accuracy, measured by the Pearson correlation between imputed and true genotypes, by 3% to 101% (mean = 38%) compared to the TOPMed panel and by 3% to 73% (mean = 27%) compared to the Genome Asia Pilot panel across different allele frequencies. The LASI-DAD reference panel is publicly available to benefit future studies.
No takes yet. Share an insight, caveat, or question.
LI et al. (2026) studied this question. The LASI-DAD panel from 2,680 Indians improved polygenic risk score prediction by up to 35.1% and genotype imputation accuracy by up to 101% versus existing panels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: